1. FRI0331 Apremilast for the treatment of behçet's syndrome: a phase ii randomized, placebo-controlled, double-blind study. (23rd January 2014) Authors: Hatemi, G.; Melikoglu, M.; Tunc, R.; Korkmaz, C.; Ozturk, B. T.; Mat, C.; Merkel, P. A.; Calamia, K. T.; Liu, Z.; Pineda, L.; Stevens, R. M.; Yazici, H.; Yazici, Y. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A486 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LB0001 Long-Term (52-Week) Results of a Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis. (23rd January 2014) Authors: Kavanaugh, A.; Mease, P. J.; Adebajo, A. O.; Wollenhaupt, J.; Hu, C.; Shah, K.; Stevens, R. M.; Gomez-Reino, J. J. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A163 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗